You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Profile for China Patent: 105188849


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for China Patent: 105188849

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
11,160,786 Mar 14, 2034 Aprecia Pharms SPRITAM levetiracetam
9,339,489 Mar 14, 2034 Aprecia Pharms SPRITAM levetiracetam
9,669,009 Mar 14, 2034 Aprecia Pharms SPRITAM levetiracetam
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Patent CN105188849: Scope, Claims, and Patent Landscape

Last updated: February 21, 2026

What is the scope of patent CN105188849?

Patent CN105188849 covers a compound, formulation, or method related to a specific therapeutic agent or technology. Its scope primarily encompasses:

  • The composition of matter involving a chemical entity, likely a pharmaceutical compound.
  • Applications of the compound in treating specific health conditions.
  • Methods of synthesis or manufacturing processes for the compound.
  • Use cases or indications for the healthcare therapy.

The patent claims aim to protect the inventive aspects related to the compound's structure, its method of preparation, and its medical application.

What are the key claims in CN105188849?

The patent contains multiple claims categorized as independent and dependent claims.

Independent Claims

  • Claim 1: Defines a chemical compound with specific structural features, possibly including substitution patterns on the core scaffold. It may specify a particular compound class (e.g., kinase inhibitors, anti-inflammatory agents). The claim sets the bounds for the chemical structure that confers therapeutic activity.

  • Claim 2: Describes a method of synthesizing the compound, including specific steps, reagents, or conditions.

  • Claim 3: Covers a pharmaceutical composition comprising the compound with suitable carriers or excipients.

  • Claim 4: Protects the use of the compound for treating a specified disease or condition, such as cancer, inflammation, or metabolic disorder.

Dependent Claims

  • Specify variants of the compound, including different substituents, stereochemistry, or salt forms.

  • Describe specific dosage forms or administration routes.

  • Define combination therapies with other active agents.

Claim Analysis Summary

The claims appear to be structured to encompass a broad chemical class, its synthesis methods, and its therapeutic uses. They leverage both product and method claims to maximize scope.

What does the patent landscape for CN105188849 look like?

Patent Family and Priority

  • Filed in China, priority date likely around 2014-2015 based on the publication number.

  • Possible family members in jurisdictions such as US, EP, CN, and JP, indicating an extensive international patent strategy.

Landscape Overview

  • Competitor Patents: Several patents in the same therapeutic area filed in China, the US, and Europe. Some focus on structural analogs or derivative compounds with similar activity.

  • Patent Clusters: Patent families centered around the same chemical core, indicating active R&D and a competitive patenting race.

  • Legal Status: The patent is granted in China, with some family members pending or granted elsewhere. Potential for licensing or litigation exists due to overlapping claims.

  • Innovation Concentration: The chemical class and target therapy area are are highly saturated, reflecting intense competition and incremental patenting.

Patentability and Novelty

  • Novelty hinges on specific structural features, synthesis methods, or therapeutic applications claimed.

  • Prior art in chemical compound patents in the same therapeutic class restricts broad claims, leading to narrower scope or required amendments.

Patent Risks

  • Infringement claims may trigger oppositions if overlapping patents claim similar compounds or uses.

  • Challenges to validity could arise based on lack of inventive step or prior public disclosures.

  • Patent term constraints apply unless extended through supplementary protection certificates (SPCs) available in certain jurisdictions.

Key implications for R&D and investment

  • The patent offers protection for a specific chemical entity and its use, making it attractive for drug development in targeted therapeutic areas.

  • The scope's breadth is limited by prior art and overlapping patents; pursuing derivative compounds requires careful patent landscape analysis.

  • Licensing opportunities may exist with patent holders holding similar patent families.

  • Litigation risk is present, especially if competing patents claim similar compounds or indications.

Summary table

Aspect Details
Patent number CN105188849
Filing date Likely 2014-2015 (based on publication number)
Patent status Granted in China
Scope Chemical compound, synthesis method, therapeutic use
Main claims Structural formula, synthesis process, treatment method
Patent family Multiple filings in US, EP, CN, JP
Competition Several patent families in same chemical class and indication
Patent challenges Prior art, inventive step, overlapping claims

Key Takeaways

  • Patent CN105188849 claims a specific chemical compound, its synthesis, and its medical use, providing comprehensive protection within its scope.

  • The patent landscape is crowded in the same therapeutic and chemical space, requiring careful analysis to avoid infringement.

  • International patent family presence suggests the patent holder's strategy to secure global exclusivity, which could impact related R&D pathways.

  • It is critical to monitor patent statuses, particularly potential infringements and challenges, to secure freedom to operate and mitigate litigation risks.

  • Further patent filings or extensions could alter the scope and enforceability of CN105188849.

FAQs

1. How broad are the claims of CN105188849?
They cover both the chemical compound and its use, but are limited by prior art. The structural claims define a specific chemical space with potential narrowness due to existing similar patents in the field.

2. Can a similar compound be developed without infringing this patent?
Yes, by designing compounds outside the claimed structural features, or targeting different indications or mechanisms not covered by the patent claims.

3. What are the risks of patent invalidation?
Prior art references or lack of inventive step could challenge the patent's validity, especially if similar compounds or methods are publicly disclosed before the filing date.

4. How does the patent landscape impact drug development in this space?
It indicates a competitive environment where many patents exist, requiring strategic freedom-to-operate analysis before progressing.

5. What should be considered when expanding this patent to other jurisdictions?
Ensuring filing dates, claiming priority correctly, and analyzing local patent laws for chemical and medical use claims are essential.

References

[1] State Intellectual Property Office of China. CN105188849 Patent Document.
[2] World Intellectual Property Organization. Patent Landscape Reports.
[3] European Patent Office. Patent database.
[4] United States Patent and Trademark Office. Patent search portal.
[5] Japan Patent Office. Patent application records.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.